Perhaps one of the best hair loss remedy associated information of 2023 simply got here out final week (h/t “Theo”). South Korea primarily based Kangstem Biotech plans to business a hair cloning sort hair loss remedy in 2024.

They will commercialize a cloned hair follicle-based drug screening and efficacy analysis methodology; and start nonclinical efficacy analysis of hair transplants primarily based on the cloned hairs.

Kangstem Biotech hair cloning through hair follicle organoid culturing.

Kangstem Biotech to Commercialize Hair Cloning Treatment in 2024

Kangstem Biotech (South Korea) was based in 2010 and is publicly traded. Its shareholders embrace a variety of main Korean and Western corporations. Without checking this firm’s status, I might need delayed this submit to subsequent yr.

The firm focuses on cord-blood derived stem cell and different anti-aging associated remedies. They are additionally a contract improvement and manufacturing group (CDMO). I by no means heard about them until this week.

During the previous two weeks, Kangstem Biotech had two press releases which can be fairly exceptional:

  1. On December sixth, the corporate introduced plans to hurry up the commercialization and launch of skin organoids to 2024. Interestingly, they’d an replace about their artificial skin technology and Seoul National University partnership in 2021.
  2. On December twenty second, the corporate introduced plans to start commercialization of the world’s first human hair follicle organoid-based hair loss remedy in 2024.

Per the second press launch, Kangstem Biotech signed a contract with the Seoul National University Industrial Cooperation Foundation for:

“Human hair drug screening and human hair follicle production and culture technology for hair transplant materials to develop and commercialize hair loss treatment based on hair follicle organoids.”

Also take a look at the summary in Newsprime. And on Linkedin.

The firm additionally states the next per the Korean to English translation:

“This technology is the world’s first artificial production of human hair follicle organoids in a test tube, and is a technology that reproduces human hair follicles.”

Kangstem has a two pronged strategy with regards to utilization of its know-how:

  • Provide a drug screening platform for the event of hair loss or hair progress pharmaceutical remedies. They plan to launch their enterprise for hair follicle-based efficacy analysis strategies in 2024.
  • Begin non-clinical efficacy analysis of utilizing the hair follicles they tradition to be used in precise hair transplants. Also in 2024.

The authorities rules for regenerative medication in quickly getting older developed Asian international locations have turn out to be very versatile. South Korea can’t afford to attend too lengthy, contemplating that common delivery charges within the nation hit just 0.72 children per woman in 2023.

Also of significance, South Korea and Japan are each attempting to turn out to be world leaders in beauty process associated tourism.

South Korea’s Leadership in New Hair Loss Treatments

This provides yet one more new South Korean entrant within the hair cloning or hair multiplication sector. Others that I’ve lined lately embrace Epibiotech and Han Bio. For a listing of all main South Korean entitities which can be engaged on any sort of vital hair loss remedy, take a look at my web page on hair loss remedy analysis around the globe.



Source by [author_name]

Leave a comment

Your email address will not be published. Required fields are marked *